;G-protein coupled receptors (GPCRs) comprise a large superfamily of target proteins (nearly 800 different human genes encode for GPCRs) and each of them can adopt functionally distinct conformations. New chemotypes and allosteric modulation, which are the focus of this project, will facilitate the development of novel, highly selective drugs because allosteric sites are significantly less conserved between GPCR subtypes and closely related sub-families and display higher structural variation. The Medicinal Chemistry Core will synthesize new GPCR ligands as reagents to enable new crystal structures, as molecular tools to help deconvolute signaling pathways, and as innovative lead compounds. This core aims to provide such optimized molecules, working intimately with all three ofthe Projects. Collaborating with Project 3, the working plan ofthe Medicinal Chemistry Core includes the development of covalent agonists to facilitate high-resolution, active state structures ofthe M2 and MS muscarinic receptors and the synthesis of heavy atom-substituted ligands for structures of muscarinic receptors bound to allosteric modulators. To evaluate effect of allosteric ligands on binding kinetics of purified GPCRs (Project 2), fluorophore-labeled M2 and MS receptor antagonist and agonists will be developed. In the field of ligand discovery and optimization, the Medicinal Chemistry Core will work intimately with Project 1 to optimize new chemotypes identified from library docking campaigns and to develop high affinity allosteric ligands from docking hits, which must be improved by at least two order of magnitude in affinity to become valuable tools and lead compounds for drug discovery. The Medicinal Chemistry Core essentially contributes to the larger project?combining GPCR crystal structure determination with sophisticated new biophysical assays with molecular docking campaigns for new chemotypes.
The Medicinal Chemistry Core will be crucial for the progression of effective and selective allosteric GPCR modulators, which is the long-term goal of this interdisciplinary project. Not only do we expect useful reagents, and occasionally therapeutic leads, to emerge from this program, but also integrated strategies for pragmatic optimization .
|Brea, Roberto J; Cole, Christian M; Lyda, Brent R et al. (2017) In Situ Reconstitution of the Adenosine A2A Receptor in Spontaneously Formed Synthetic Liposomes. J Am Chem Soc 139:3607-3610|
|Stößel, Anne; Brox, Regine; Purkayastha, Nirupam et al. (2017) Development of molecular tools based on the dopamine D3 receptor ligand FAUC 329 showing inhibiting effects on drug and food maintained behavior. Bioorg Med Chem 25:3491-3499|
|Manglik, Aashish; Lin, Henry; Aryal, Dipendra K et al. (2016) Structure-based discovery of opioid analgesics with reduced side effects. Nature 537:185-190|
|DeVree, Brian T; Mahoney, Jacob P; Vélez-Ruiz, Gisselle A et al. (2016) Allosteric coupling from G protein to the agonist-binding pocket in GPCRs. Nature 535:182-6|
|Thal, David M; Sun, Bingfa; Feng, Dan et al. (2016) Crystal structures of the M1 and M4 muscarinic acetylcholine receptors. Nature 531:335-40|
|Mahoney, Jacob P; Sunahara, Roger K (2016) Mechanistic insights into GPCR-G protein interactions. Curr Opin Struct Biol 41:247-254|
|Thorsen, Thor Seneca; Matt, Rachel; Weis, William I et al. (2014) Modified T4 Lysozyme Fusion Proteins Facilitate G Protein-Coupled Receptor Crystallogenesis. Structure 22:1657-64|
|Kruse, Andrew C; Li, Jianhua; Hu, Jianxin et al. (2014) Novel insights into M3 muscarinic acetylcholine receptor physiology and structure. J Mol Neurosci 53:316-23|
|Kruse, Andrew C; Kobilka, Brian K; Gautam, Dinesh et al. (2014) Muscarinic acetylcholine receptors: novel opportunities for drug development. Nat Rev Drug Discov 13:549-60|
|Kruse, Andrew C; Weiss, Dahlia R; Rossi, Mario et al. (2013) Muscarinic receptors as model targets and antitargets for structure-based ligand discovery. Mol Pharmacol 84:528-40|
Showing the most recent 10 out of 11 publications